Healio

Semaglutide reduces CV events more than tirzepatide in real-world study

Please provide your email address to receive an email when new articles are posted on . In a real-world cohort of patients with obesity and heart disease but not diabetes, semaglutide prevented more ...

FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not ha…

Novo Nordisk announced today that the US Food and Drug Administration (FDA) has approved Rybelsus®, the only oral GLP-1 ...
Pharmabiz

Novo Nordisk's Rybelsus gets US FDA approval for CV risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event

Novo Nordisk's Rybelsus gets US FDA approval for CV risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event ...
Healio

Acoramidis reduces cumulative CV outcomes in patients with cardiac amyloidosis

Please provide your email address to receive an email when new articles are posted on . Acoramidis reduced cumulative CV outcomes vs. placebo in patients with cardiac amyloidosis. The curves separated ...